Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT00903760
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
- Conditions
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00882102
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00882206
- Locations
- 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 204
- Registration Number
- NCT00867672
- Locations
- 🇩🇪
Vivantes Klinikum Neukölln, Berlin, Germany
🇩🇪Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
🇩🇪Klinikum der Technischen Universität Aachen, Aachen, Germany
A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 13
- Registration Number
- NCT00861874
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Myelodysplastic Syndrome With Excess Blastst(8;21)High Risk Myelodysplastic SyndromeInv(16)t(16;16)Untreated Adult Acute Myeloid Leukemiade Novo Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 270
- Registration Number
- NCT00801489
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00791271
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 122
- Registration Number
- NCT00778375
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00760084
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 134
- Registration Number
- NCT00748527
- Locations
- 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧Hammersmith Hospital, London, England, United Kingdom
🇬🇧Saint Bartholomew's Hospital, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.